Aprogen Medicines Inc. (007460.KS)
KRW 816.0
(-3.09%)
KRW 816.0
(-3.09%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 150.57 Billion | 78.34 Billion | 141.24 Billion | 127.14 Billion | 78.24 Billion | 51.04 Billion |
| Cost of Revenue | 116.37 Billion | 72.19 Billion | 109.99 Billion | 92.67 Billion | 58.89 Billion | 41.86 Billion |
| Gross Profit | 34.19 Billion | 6.15 Billion | 31.25 Billion | 34.46 Billion | 19.35 Billion | 9.18 Billion |
| Operating Expenses | 118.79 Billion | 120.5 Billion | 33.92 Billion | 30.49 Billion | 16.78 Billion | 7.6 Billion |
| Selling, General and Administrative Expenses | 74.72 Billion | 40.96 Billion | 15.68 Billion | 12.06 Billion | 6.82 Billion | 620.96 Million |
| Research and Development Expenses | 44.07 Billion | 38.56 Billion | 1.97 Billion | 1.02 Billion | 1.87 Billion | 4.38 Billion |
| Other Expenses | 2.55 Billion | 40.98 Billion | 16.26 Billion | 17.4 Billion | 8.09 Billion | 207.36 Million |
| Cost and Expenses | 239.44 Billion | 192.7 Billion | 143.91 Billion | 123.17 Billion | 75.68 Billion | 49.47 Billion |
| Operating Income | -88.86 Billion | -114.35 Billion | -2.67 Billion | 5.62 Billion | 41.43 Billion | 1.57 Billion |
| Interest Expense | 1.76 Billion | 9.9 Billion | 11.42 Billion | 5.23 Billion | 9.14 Billion | 20.71 Billion |
| Income Tax Expense | 2.04 Billion | 473.8 Million | 3.31 Billion | -6.44 Billion | -1.4 Billion | 2.91 Billion |
| Earnings before Tax | -95.23 Billion | -115.61 Billion | -9.18 Billion | -39.11 Billion | 16.92 Billion | -22 Billion |
| Net Income | -55.61 Billion | -116.08 Billion | -12.5 Billion | -32.66 Billion | 18.32 Billion | -32.1 Billion |
| Earnings Per Share Basic | -235.50 | -1730.97 | -194.12 | -577.78 | 402.11 | -1895.62 |
| Earnings Per Share Diluted | -235.50 | -1720.75 | -194.12 | -577.78 | 402.11 | -1895.62 |
| Weighted Average Shares Outstanding | 236.17 Million | 67.06 Million | 64.39 Million | 56.54 Million | 45.57 Million | 16.93 Million |
| Weighted Average Shares Outstanding (Diluted) | 236.17 Million | 67.46 Million | 64.39 Million | 56.54 Million | 45.57 Million | 16.93 Million |
| Gross Margin | 0.23 | 0.08 | 0.22 | 0.27 | 0.25 | 0.18 |
| EBIT Margin | -0.44 | -0.83 | -0.05 | 0.08 | 0.57 | -0.02 |
| Profit Margin | -0.37 | -1.48 | -0.09 | -0.26 | 0.23 | -0.63 |
| EBITDA | -65.89 Billion | -76.14 Billion | -70.54 Billion | -20.34 Billion | 40.81 Billion | 741.42 Million |
| Earnings Before Tax Margin | -0.59 | -1.46 | -0.02 | 0.04 | 0.53 | 0.03 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 35.59 Billion | 38.08 Billion | 37.38 Billion | 150.57 Billion | 39.85 Billion | 37.37 Billion |
| Cost of Revenue | 28.67 Billion | 31.11 Billion | 7.66 Billion | 126.75 Billion | 34.75 Billion | 51.54 Billion |
| Gross Profit | 6.91 Billion | 6.96 Billion | 29.72 Billion | 23.82 Billion | 5.1 Billion | -14.16 Billion |
| Operating Expenses | 25.98 Billion | 26.19 Billion | 60.78 Billion | 118.79 Billion | -28.48 Billion | -9.13 Billion |
| Selling, General and Administrative Expenses | 14.51 Billion | 14.71 Billion | 49.26 Billion | - | 28.48 Billion | 9.13 Billion |
| Research and Development Expenses | 11.3 Billion | 11.29 Billion | 11.52 Billion | - | 17.07 Billion | - |
| Other Expenses | -168.96 Million | -173.63 Million | 631.29 Million | 2.55 Billion | -56.97 Billion | -18.27 Billion |
| Cost and Expenses | 54.66 Billion | 57.3 Billion | 68.45 Billion | 245.54 Billion | 34.75 Billion | 51.54 Billion |
| Operating Income | -19.07 Billion | -19.22 Billion | -31.06 Billion | -94.97 Billion | -23.38 Billion | -23.3 Billion |
| Interest Expense | - | 130.59 Million | 427.5 Million | 1.76 Billion | - | 1.86 Billion |
| Income Tax Expense | 4.46 Billion | 5.93 Million | -1.97 Billion | 2.04 Billion | 3.94 Billion | 176.65 Million |
| Earnings before Tax | -14.3 Billion | -18.24 Billion | -29 Billion | -95.23 Billion | -26.7 Billion | -21.66 Billion |
| Net Income | -2.86 Billion | -29.76 Billion | 17.31 Billion | -55.61 Billion | -33.38 Billion | -14.22 Billion |
| Earnings Per Share Basic | -11.47 | -121.96 | 70.95 | - | -141.52 | -61.09 |
| Earnings Per Share Diluted | -11.47 | -121.96 | 70.95 | - | -141.52 | -61.00 |
| Weighted Average Shares Outstanding | 250.13 Million | 244.07 Million | 244.07 Million | 236.17 Million | 235.86 Million | 232.91 Million |
| Weighted Average Shares Outstanding (Diluted) | 250.13 Million | 244.07 Million | 244.07 Million | 236.17 Million | 235.86 Million | 233.25 Million |
| Gross Margin | 0.19 | 0.18 | 0.79 | 0.16 | 0.13 | -0.38 |
| EBIT Margin | -0.38 | -0.35 | -0.65 | - | 0.13 | -0.38 |
| Profit Margin | -0.08 | -0.78 | 0.46 | -0.37 | -0.84 | -0.38 |
| EBITDA | -13.46 Billion | -13.32 Billion | -24.26 Billion | - | 5.1 Billion | -14.16 Billion |
| Earnings Before Tax Margin | -0.54 | -0.50 | -0.83 | -0.63 | -0.59 | -0.62 |
019685
LH-R
001275
HERB
TCPC
310210